Glenmark files clinical trial application for its anti-body
Advertisement
Glenmark pharmaceuticals has filed an application for phase 1 clinical trial for its bi specific antibody GBR 1302 with the German authorities.
After confirming its reports in the pre clinical trial phase, the GBR 1302 has shown positive result for treating cancer cells including, breast cancer.
Glenmark Pharmaceuticals SA, a wholly-owned subsidiary of the company, has submitted a clinical trial application for GBR 1302 to the Paul-Ehrlich Institute in Germany, Glenmark Pharmaceuticals said in a statement.
"During the pre-clinical characterisation of the bi- specific antibody, we have discovered that GBR 1302 does not only kill trastuzumab resistant cancer cells, but also very efficiently kills cancer cells with a weak expression of HER2...," Glenmark Pharmaceuticals Chief Scientific Officer & President - Biologics Michael Buschle said.
GBR 1302 material for phase I clinical trials was manufactured at the Glenmark GMP production unit in Switzerland.
A bi-specific monoclonal antibody is an artificial protein that is composed of fragments of two different monoclonal antibodies and consequently binds two different types of antigens.
With the addition of GBR 1302 to the pipeline, Glenmark has now four monoclonal antibodies in the novel biologics entity (NBE) pipeline, with three of them undergoing active clinical development.
After confirming its reports in the pre clinical trial phase, the GBR 1302 has shown positive result for treating cancer cells including, breast cancer.
Glenmark Pharmaceuticals SA, a wholly-owned subsidiary of the company, has submitted a clinical trial application for GBR 1302 to the Paul-Ehrlich Institute in Germany, Glenmark Pharmaceuticals said in a statement.
"During the pre-clinical characterisation of the bi- specific antibody, we have discovered that GBR 1302 does not only kill trastuzumab resistant cancer cells, but also very efficiently kills cancer cells with a weak expression of HER2...," Glenmark Pharmaceuticals Chief Scientific Officer & President - Biologics Michael Buschle said.
GBR 1302 material for phase I clinical trials was manufactured at the Glenmark GMP production unit in Switzerland.
A bi-specific monoclonal antibody is an artificial protein that is composed of fragments of two different monoclonal antibodies and consequently binds two different types of antigens.
With the addition of GBR 1302 to the pipeline, Glenmark has now four monoclonal antibodies in the novel biologics entity (NBE) pipeline, with three of them undergoing active clinical development.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.